Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-24
2010-06-08
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07732407
ABSTRACT:
A method for treating demyelinating central nervous system diseases in a subject that comprises administering to the subject a composition comprising a therapeutically active amount of colony stimulating factor or CSF-like ligand. In a preferred embodiment of the present invention, the CSF is a GM-CSF. In a most preferred embodiment of the present invention, CSF is sargramostim.
REFERENCES:
patent: 5162111 (1992-11-01), Grabstein et al.
patent: 5451662 (1995-09-01), Naveh et al.
patent: 5679715 (1997-10-01), Harris
patent: 5716946 (1998-02-01), DeLuca et al.
patent: 5837460 (1998-11-01), Von Feldt et al.
patent: 6013253 (2000-01-01), Martin et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: 6274175 (2001-08-01), Gombotz et al.
patent: 6309632 (2001-10-01), Agosti
patent: 6469055 (2002-10-01), Lee et al.
patent: 6576231 (2003-06-01), Echols
patent: 6623736 (2003-09-01), Tobinick
patent: 2005/0244965 (2005-11-01), Weiss
patent: WO 00/77028 (2000-12-01), None
patent: WO 02/13862 (2002-02-01), None
patent: PCT/US03/32716 (2003-10-01), None
Leukine product information, downloaded from internet Oct. 22, 2008.
Bartholome, et al.; Interferon-B inhibits Th1 Responses at the Dendritic Cell Level Relevance to Multiple Sclerosis; Acta Neurologica Belgica; Belgium; Mar. 1999; pp. 44-52.
Huang, et al.; Interferon-Beta Induces the Development of Type 2 Dendritic Cells; Cytokine; vol. 13; No. 5; Mar. 2001; pp. 264-271.
Hayashi, et al.; Granulocyte—Macrophage Colony Stimulating Factor Inhibits Class II Major Histocompatibility Complex Expression and Antigen Presentation by Microglia; Journal of Neuroimmunology; vol. 48; No. 1; 1993; pp. 23-32.
Duddy, et al.; Monocyte-Derived Dendritic Cells: A Potential Target for Therapy in Mulitple Sclerosis (MS); Clinical and Experimental Immunology; vol. 123; No. 2; Feb. 2001; pp. 280-287.
Openshaw, et al.; Multiple Sclerosis Flares Associated with Recombinant Granulocyte Colony-Stimulating Factor; Neurology; vol. 54; No. 11; Jun. 13, 2000; pp. 2147-2150.
McQualter, et al.; Granulocyte Macrophage Colony-Stimulating Factor: A New Putative Therapeutic Target in Multiple Sclerosis; Journal of Experimental Medicine, Tokyo, JP; vol. 194; No. 7; Oct. 1, 2001; pp. 873-881.
Smith, et al.; Macrophage and Microglial Responses to Cytokines In Vitro: Phagocytic Activity, Proteolytic Enzyme Release, and Free Radical Production; Journal of Neuroscience Research; vol. 54; No. 1; Oct. 1, 1998; pp. 68-78.
Zavala, et al.; G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokin-Based Immune Deviation; The Journal of Immunology; vol. 168; No. 4; Feb. 15, 2002; pp. 2011-2019.
Polman, et al.; Drug Treatment of Multiple Sclerosis; British Medical Journal; 321; Aug. 19-26, 2000; pp. 490-494.
NCI terminology browser for sargramostim, accessed Feb. 10, 2006, version from Dec. 2005.
Kolker Daniel E.
Myers, Jr. Richard S.
Stites & Harbison PLLC
LandOfFree
Method for treatment of demyelinating central nervous system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of demyelinating central nervous system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of demyelinating central nervous system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175333